Olumiant Union européenne - français - EMA (European Medicines Agency)

olumiant

eli lilly nederland b.v. - baricitinib - arthrite, rhumatoïde - immunosuppresseurs - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant peut être utilisé en monothérapie ou en association avec le méthotrexate. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Olumiant 2 mg comprimés pelliculés Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

olumiant 2 mg comprimés pelliculés

eli lilly (suisse) sa - baricitinibum - comprimés pelliculés - comprimé pelliculé: baricitinibum 2 mg, mannitolum 52 mg, cellulosum microcristallinum, carmellosum natricum conexum, magnesii stearas, pellicule: poly(alcohol vinylicus), macrogolum, talcum, lecithinum ex soja, e 171, e 172 (rubrum), pro compresso obducto, natrium 0.7608 mg. - polyarthrite rhumatoïde / dermatite atopique / covid 19 / alopecia areata - synthetika

Olumiant 4 mg comprimés pelliculés Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

olumiant 4 mg comprimés pelliculés

eli lilly (suisse) sa - baricitinibum - comprimés pelliculés - comprimé pelliculé: baricitinibum 4 mg, mannitolum 50 mg, cellulosum microcristallinum, carmellosum natricum conexum, magnesii stearas, pellicule: poly(alcohol vinylicus), macrogolum, talcum, lecithinum ex soja, color.: e 171, e 172 (rubrum), pro compresso obducto, natrium 0.7608 mg. - polyarthrite rhumatoïde / dermatite atopique / covid 19 / alopecia areata - synthetika

OLUMIANT Comprimé Canada - français - Health Canada

olumiant comprimé

eli lilly canada inc - baricitinib - comprimé - 2mg - baricitinib 2mg - immunosuppressive agents

Ontozry Union européenne - français - EMA (European Medicines Agency)

ontozry

angelini pharma s.p.a - cenobamate - Épilepsie - des antiépileptiques,des - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.

Ontozry 12.5 mg Comprimés Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

ontozry 12.5 mg comprimés

angelini pharma s.p.a., rom, zweigniederlassung zug - cenobamatum - comprimés - cenobamatum 12.5 mg, cellulosum microcristallinum, lactosum monohydricum 39.67 mg, carboxymethylamylum natricum a corresp. natrium 0.16 mg, silica colloidalis anhydrica, magnesii stearas, pro compresso. - antieptileptikum - synthetika

Ontozry 25 mg Comprimés pelliculés Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

ontozry 25 mg comprimés pelliculés

angelini pharma s.p.a., rom, zweigniederlassung zug - cenobamatum - comprimés pelliculés - cenobamatum 25 mg, cellulosum microcristallinum, lactosum monohydricum 79.34 mg, carboxymethylamylum natricum a corresp. natrium 0.32 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum, talcum, e 172 (flavum), e 172 (rubrum), e 132, pro compresso obducto. - antieptileptikum - synthetika

Ontozry 50 mg Comprimés pelliculés Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

ontozry 50 mg comprimés pelliculés

angelini pharma s.p.a., rom, zweigniederlassung zug - cenobamatum - comprimés pelliculés - cenobamatum 50 mg, cellulosum microcristallinum, lactosum monohydricum 158.68 mg, carboxymethylamylum natricum a corresp. natrium 0.64 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 4000, talcum, e 172 (flavum), pro compresso obducto. - antieptileptikum - synthetika

Ontozry 100 mg Comprimés pelliculés Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

ontozry 100 mg comprimés pelliculés

angelini pharma s.p.a., rom, zweigniederlassung zug - cenobamatum - comprimés pelliculés - cenobamatum 100 mg, cellulosum microcristallinum, lactosum monohydricum 108.68 mg, carboxymethylamylum natricum a corresp. natrium 0.64 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum, talcum, e 172 (flavum), e 172 (rubrum), e 132, pro compresso obducto. - antieptileptikum - synthetika

Ontozry 150 mg Comprimés pelliculés Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

ontozry 150 mg comprimés pelliculés

angelini pharma s.p.a., rom, zweigniederlassung zug - cenobamatum - comprimés pelliculés - cenobamatum 150 mg, cellulosum microcristallinum, lactosum monohydricum 163.02 mg, carboxymethylamylum natricum a corresp. natrium 0.96 mg, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 4000, talcum, e 172 (flavum), e 172 (rubrum), pro compresso obducto. - antieptileptikum - synthetika